Published in J Biol Chem on June 05, 1986
Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor. Proc Natl Acad Sci U S A (2003) 5.95
Anthrax toxin protective antigen is activated by a cell surface protease with the sequence specificity and catalytic properties of furin. Proc Natl Acad Sci U S A (1992) 4.91
Contribution of individual toxin components to virulence of Bacillus anthracis. Infect Immun (1991) 4.17
A phenylalanine clamp catalyzes protein translocation through the anthrax toxin pore. Science (2005) 4.10
Susceptibility of mitogen-activated protein kinase kinase family members to proteolysis by anthrax lethal factor. Biochem J (2000) 3.83
Intracellular digestion of reovirus particles requires a low pH and is an essential step in the viral infectious cycle. J Virol (1987) 3.65
Anthrax toxin: channel-forming activity of protective antigen in planar phospholipid bilayers. Proc Natl Acad Sci U S A (1989) 3.54
On the role of macrophages in anthrax. Proc Natl Acad Sci U S A (1993) 3.34
Cellular and systemic effects of anthrax lethal toxin and edema toxin. Mol Aspects Med (2009) 2.93
Proteolytic activation of bacterial toxins by eukaryotic cells is performed by furin and by additional cellular proteases. Infect Immun (1995) 2.87
Anthrax lethal toxin and Salmonella elicit the common cell death pathway of caspase-1-dependent pyroptosis via distinct mechanisms. Proc Natl Acad Sci U S A (2008) 2.82
The protective antigen component of anthrax toxin forms functional octameric complexes. J Mol Biol (2009) 2.69
Inhibitors of receptor-mediated endocytosis block the entry of Bacillus anthracis adenylate cyclase toxin but not that of Bordetella pertussis adenylate cyclase toxin. Infect Immun (1988) 2.69
Production and characterization of monoclonal antibodies to the protective antigen component of Bacillus anthracis toxin. Infect Immun (1988) 2.63
Binary bacterial toxins: biochemistry, biology, and applications of common Clostridium and Bacillus proteins. Microbiol Mol Biol Rev (2004) 2.60
Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs. Infect Immun (1997) 2.53
Mapping the lethal factor and edema factor binding sites on oligomeric anthrax protective antigen. Proc Natl Acad Sci U S A (2002) 2.51
The lethal and edema factors of anthrax toxin bind only to oligomeric forms of the protective antigen. Proc Natl Acad Sci U S A (2002) 2.31
Receptor-specific requirements for anthrax toxin delivery into cells. Proc Natl Acad Sci U S A (2005) 2.15
Anthrax protective antigen interacts with a specific receptor on the surface of CHO-K1 cells. Infect Immun (1991) 2.12
Characterization of macrophage sensitivity and resistance to anthrax lethal toxin. Infect Immun (1993) 1.97
Attenuated nontoxinogenic and nonencapsulated recombinant Bacillus anthracis spore vaccines protect against anthrax. Infect Immun (2000) 1.93
Role of toxin functional domains in anthrax pathogenesis. Infect Immun (2000) 1.93
Crystal structure of the von Willebrand factor A domain of human capillary morphogenesis protein 2: an anthrax toxin receptor. Proc Natl Acad Sci U S A (2004) 1.91
Biochemical and physiological changes induced by anthrax lethal toxin in J774 macrophage-like cells. Mol Biol Cell (1992) 1.86
Fusions of anthrax toxin lethal factor with shiga toxin and diphtheria toxin enzymatic domains are toxic to mammalian cells. Infect Immun (1994) 1.84
Production and characterization of monoclonal antibodies against the lethal factor component of Bacillus anthracis lethal toxin. Infect Immun (1990) 1.78
Identification of a receptor-binding region within domain 4 of the protective antigen component of anthrax toxin. Infect Immun (1999) 1.68
Novel broad-spectrum bis-(imidazolinylindole) derivatives with potent antibacterial activities against antibiotic-resistant strains. Antimicrob Agents Chemother (2009) 1.66
Efficiency of protection of guinea pigs against infection with Bacillus anthracis spores by passive immunization. Infect Immun (2002) 1.64
Functional analysis of Bacillus anthracis protective antigen by using neutralizing monoclonal antibodies. Infect Immun (2004) 1.64
Internalization of a Bacillus anthracis protective antigen-c-Myc fusion protein mediated by cell surface anti-c-Myc antibodies. Mol Med (1998) 1.64
Cutting edge: resistance to Bacillus anthracis infection mediated by a lethal toxin sensitive allele of Nalp1b/Nlrp1b. J Immunol (2009) 1.63
Structural basis for the unfolding of anthrax lethal factor by protective antigen oligomers. Nat Struct Mol Biol (2010) 1.62
Involvement of domain 3 in oligomerization by the protective antigen moiety of anthrax toxin. J Bacteriol (2001) 1.62
Proteolytic activation of bacterial toxins: role of bacterial and host cell proteases. Infect Immun (1994) 1.61
A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge. Infect Immun (2005) 1.61
Macrophage-derived cell lines do not express proinflammatory cytokines after exposure to Bacillus anthracis lethal toxin. Infect Immun (2001) 1.60
Selective inhibitor of endosomal trafficking pathways exploited by multiple toxins and viruses. Proc Natl Acad Sci U S A (2013) 1.60
A recombinant carboxy-terminal domain of the protective antigen of Bacillus anthracis protects mice against anthrax infection. Infect Immun (2002) 1.60
Role of macrophage oxidative burst in the action of anthrax lethal toxin. Mol Med (1994) 1.60
Mapping dominant-negative mutations of anthrax protective antigen by scanning mutagenesis. Proc Natl Acad Sci U S A (2003) 1.59
Oligomerization of anthrax toxin protective antigen and binding of lethal factor during endocytic uptake into mammalian cells. Infect Immun (1999) 1.58
Anthrax edema toxin differentially regulates lipopolysaccharide-induced monocyte production of tumor necrosis factor alpha and interleukin-6 by increasing intracellular cyclic AMP. Infect Immun (1994) 1.57
Role of N-terminal amino acids in the potency of anthrax lethal factor. PLoS One (2008) 1.54
Anthrax toxin targeting of myeloid cells through the CMG2 receptor is essential for establishment of Bacillus anthracis infections in mice. Cell Host Microbe (2010) 1.51
Enhancement of anthrax lethal toxin cytotoxicity: a subset of monoclonal antibodies against protective antigen increases lethal toxin-mediated killing of murine macrophages. Infect Immun (2004) 1.47
Expression of the Salmonella virulence plasmid gene spvB in cultured macrophages and nonphagocytic cells. Infect Immun (1993) 1.46
Membrane translocation by anthrax toxin. Mol Aspects Med (2009) 1.42
Matrix metalloproteinase-activated anthrax lethal toxin demonstrates high potency in targeting tumor vasculature. J Biol Chem (2007) 1.41
Ratcheting up protein translocation with anthrax toxin. Protein Sci (2012) 1.38
Role of the protective antigen octamer in the molecular mechanism of anthrax lethal toxin stabilization in plasma. J Mol Biol (2010) 1.36
NLRP1-dependent pyroptosis leads to acute lung injury and morbidity in mice. J Immunol (2012) 1.34
Proteasome activity is required for anthrax lethal toxin to kill macrophages. Infect Immun (1999) 1.32
Calcium is required for the expression of anthrax lethal toxin activity in the macrophagelike cell line J774A.1. Infect Immun (1989) 1.31
Immunological analysis of cell-associated antigens of Bacillus anthracis. Infect Immun (1988) 1.30
Vaccination against anthrax with attenuated recombinant strains of Bacillus anthracis that produce protective antigen. Infect Immun (1999) 1.26
Retrocyclins kill bacilli and germinating spores of Bacillus anthracis and inactivate anthrax lethal toxin. J Biol Chem (2006) 1.25
Fused polycationic peptide mediates delivery of diphtheria toxin A chain to the cytosol in the presence of anthrax protective antigen. Proc Natl Acad Sci U S A (1996) 1.22
Anthrax toxin protective antigen: inhibition of channel function by chloroquine and related compounds and study of binding kinetics using the current noise analysis. Biophys J (2004) 1.20
Molecular cloning and expression of the Bacillus anthracis edema factor toxin gene: a calmodulin-dependent adenylate cyclase. J Bacteriol (1988) 1.18
Anthrax lethal factor represses glucocorticoid and progesterone receptor activity. Proc Natl Acad Sci U S A (2003) 1.16
Functional analysis of the carboxy-terminal domain of Bacillus anthracis protective antigen. Infect Immun (1999) 1.14
Induction of protective immunity to anthrax lethal toxin with a nonhuman primate adenovirus-based vaccine in the presence of preexisting anti-human adenovirus immunity. Infect Immun (2005) 1.13
Lethal factor active-site mutations affect catalytic activity in vitro. Infect Immun (1998) 1.12
A mathematical simulation of the inflammatory response to anthrax infection. Shock (2008) 1.11
Cell entry and cAMP imaging of anthrax edema toxin. EMBO J (2006) 1.09
Targeting HIV proteins to the major histocompatibility complex class I processing pathway with a novel gp120-anthrax toxin fusion protein. Proc Natl Acad Sci U S A (1997) 1.09
Direct proteolytic cleavage of NLRP1B is necessary and sufficient for inflammasome activation by anthrax lethal factor. PLoS Pathog (2013) 1.09
Anthrax and the inflammasome. Microbes Infect (2011) 1.06
Activation of the NLRP1b inflammasome independently of ASC-mediated caspase-1 autoproteolysis and speck formation. Nat Commun (2014) 1.06
Mucosal or parenteral administration of microsphere-associated Bacillus anthracis protective antigen protects against anthrax infection in mice. Infect Immun (2002) 1.05
LRP5 and LRP6 are not required for protective antigen-mediated internalization or lethality of anthrax lethal toxin. PLoS Pathog (2007) 1.05
Anthrax edema toxin requires influx of calcium for inducing cyclic AMP toxicity in target cells. Infect Immun (2002) 1.05
Membrane translocation of binary actin-ADP-ribosylating toxins from Clostridium difficile and Clostridium perfringens is facilitated by cyclophilin A and Hsp90. Infect Immun (2011) 1.05
Chemical genetics reveals a kinase-independent role for protein kinase R in pyroptosis. Nat Chem Biol (2013) 1.04
Anthrax toxin receptor drives protective antigen oligomerization and stabilizes the heptameric and octameric oligomer by a similar mechanism. PLoS One (2010) 1.03
Treatment of experimental anthrax with recombinant capsule depolymerase. Antimicrob Agents Chemother (2007) 1.02
Characterization of dominant-negative forms of anthrax protective antigen. Mol Med (2003) 1.01
Expression of the Bacillus anthracis protective antigen gene by baculovirus and vaccinia virus recombinants. Infect Immun (1990) 1.00
Potent inhibitors of anthrax lethal factor from green tea. EMBO Rep (2004) 1.00
Charge requirements for proton gradient-driven translocation of anthrax toxin. J Biol Chem (2011) 1.00
Anthrax lethal factor and edema factor act on conserved targets in Drosophila. Proc Natl Acad Sci U S A (2006) 1.00
Fermentation, purification, and characterization of protective antigen from a recombinant, avirulent strain of Bacillus anthracis. Appl Environ Microbiol (1998) 0.99
Analysis of the Fc gamma receptor-dependent component of neutralization measured by anthrax toxin neutralization assays. Clin Vaccine Immunol (2009) 0.99
Antibodies against anthrax: mechanisms of action and clinical applications. Toxins (Basel) (2011) 0.99
Role of CypA and Hsp90 in membrane translocation mediated by anthrax protective antigen. Cell Microbiol (2010) 0.98
GeneChip analyses of global transcriptional responses of murine macrophages to the lethal toxin of Bacillus anthracis. Infect Immun (2005) 0.98
Anthrax: A disease of biowarfare and public health importance. World J Clin Cases (2015) 0.97
Death at Sverdlovsk: what have we learned? Am J Pathol (1994) 0.96
Anthrax edema toxin induces maturation of dendritic cells and enhances chemotaxis towards macrophage inflammatory protein 3beta. Infect Immun (2009) 0.95
Anthrax toxin entry into polarized epithelial cells. Infect Immun (1999) 0.95
Maturation modulates caspase-1-independent responses of dendritic cells to Anthrax lethal toxin. Cell Microbiol (2008) 0.95
Cloned diphtheria toxin within the periplasm of Escherichia coli causes lethal membrane damage at low pH. Proc Natl Acad Sci U S A (1989) 0.94
Disruption of anthrax toxin binding with the use of human antibodies and competitive inhibitors. Infect Immun (1999) 0.94
Protein synthesis is required for expression of anthrax lethal toxin cytotoxicity. Infect Immun (1994) 0.93
Protection from anthrax toxin-mediated killing of macrophages by the combined effects of furin inhibitors and chloroquine. Antimicrob Agents Chemother (2005) 0.93
Anthrax toxin protective antigen--insights into molecular switching from prepore to pore. Protein Sci (2012) 0.92
Domain flexibility modulates the heterogeneous assembly mechanism of anthrax toxin protective antigen. J Mol Biol (2011) 0.91
The cytotoxic activity of Bacillus anthracis lethal factor is inhibited by leukotriene A4 hydrolase and metallopeptidase inhibitors. Biochem J (1996) 0.91
Tularemia as a biological weapon: medical and public health management. JAMA (2001) 13.23
Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA (2000) 8.45
Anthrax as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA (1999) 7.06
Clinical recognition and management of patients exposed to biological warfare agents. JAMA (1997) 4.67
In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine (2001) 3.03
Diversity in a variable-number tandem repeat from Yersinia pestis. J Clin Microbiol (2000) 3.03
Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine. Vaccine (1998) 2.75
Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine (1998) 2.74
The pathology of experimental anthrax in rabbits exposed by inhalation and subcutaneous inoculation. Arch Pathol Lab Med (1998) 2.58
Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs. Infect Immun (1997) 2.53
Anthrax as a potential biological warfare agent. Arch Intern Med (1998) 2.40
Pathology of experimental inhalation anthrax in the rhesus monkey. Lab Invest (1995) 2.28
Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin. Vaccine (2001) 2.23
Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis. Infect Immun (1996) 2.17
Characterization of lethal factor binding and cell receptor binding domains of protective antigen of Bacillus anthracis using monoclonal antibodies. Microbiology (1996) 2.16
Fraction 1 capsular antigen (F1) purification from Yersinia pestis CO92 and from an Escherichia coli recombinant strain and efficacy against lethal plague challenge. Infect Immun (1996) 2.09
Pathology of experimental pneumonic plague produced by fraction 1-positive and fraction 1-negative Yersinia pestis in African green monkeys (Cercopithecus aethiops). Arch Pathol Lab Med (1996) 2.04
Comparative safety and efficacy against Bacillus anthracis of protective antigen and live vaccines in mice. Microb Pathog (1988) 2.03
Pathogenesis and genetic control of resistance to the Sterne strain of Bacillus anthracis. Microb Pathog (1988) 1.98
Internalization and processing of Bacillus anthracis lethal toxin by toxin-sensitive and -resistant cells. J Biol Chem (1989) 1.93
Studies on the role of plasminogen activator in systemic infection by virulent Yersinia pestis strain C092. Microb Pathog (1997) 1.88
Anthrax lethal factor inhibition. Proc Natl Acad Sci U S A (2005) 1.83
Production and characterization of monoclonal antibodies against the lethal factor component of Bacillus anthracis lethal toxin. Infect Immun (1990) 1.78
Macrophage-derived cell lines do not express proinflammatory cytokines after exposure to Bacillus anthracis lethal toxin. Infect Immun (2001) 1.60
Anthrax edema toxin differentially regulates lipopolysaccharide-induced monocyte production of tumor necrosis factor alpha and interleukin-6 by increasing intracellular cyclic AMP. Infect Immun (1994) 1.57
Short- and long-term efficacy of single-dose subunit vaccines against Yersinia pestis in mice. Am J Trop Med Hyg (1998) 1.49
Antibiotic treatment of experimental pneumonic plague in mice. Antimicrob Agents Chemother (1998) 1.44
Protection of mice from fatal bubonic and pneumonic plague by passive immunization with monoclonal antibodies against the F1 protein of Yersinia pestis. Am J Trop Med Hyg (1997) 1.33
Calcium is required for the expression of anthrax lethal toxin activity in the macrophagelike cell line J774A.1. Infect Immun (1989) 1.31
Vaccination against anthrax with attenuated recombinant strains of Bacillus anthracis that produce protective antigen. Infect Immun (1999) 1.26
From principles to practice: a spatial approach to systematic conservation planning in the deep sea. Proc Biol Sci (2013) 1.25
Global assessment of the status of coral reef herbivorous fishes: evidence for fishing effects. Proc Biol Sci (2013) 1.20
Anthrax vaccine: increasing intervals between the first two doses enhances antibody response in humans. Vaccine (2000) 1.20
Functional characterization of protease-treated Bacillus anthracis protective antigen. J Biol Chem (1992) 1.20
Distribution, size frequency, and sex ratios of blacktip reef sharks Carcharhinus melanopterus at Palmyra Atoll: a predator-dominated ecosystem. J Fish Biol (2009) 1.17
Tackling anthrax. Nature (2001) 1.16
Anthrax vaccine: short-term safety experience in humans. Vaccine (2001) 1.15
Serum concentrations of penicillin, doxycycline, and ciprofloxacin during prolonged therapy in rhesus monkeys. J Infect Dis (1992) 1.11
Genome-based bioinformatic selection of chromosomal Bacillus anthracis putative vaccine candidates coupled with proteomic identification of surface-associated antigens. Infect Immun (2003) 1.11
Association of Bacillus anthracis capsule with lethal toxin during experimental infection. Infect Immun (2008) 1.08
Immune response to Yersinia outer proteins and other Yersinia pestis antigens after experimental plague infection in mice. Infect Immun (1999) 1.08
Protective efficacy of recombinant Yersinia outer proteins against bubonic plague caused by encapsulated and nonencapsulated Yersinia pestis. Infect Immun (1999) 1.04
Structure-function analysis of Bacillus anthracis edema factor by using monoclonal antibodies. Biochem Biophys Res Commun (1994) 1.04
Production of bladder stones by human T mycoplasmas. Nature (1974) 1.01
Medical therapy of experimental infection stones. Urology (1977) 0.96
Application of carbohydrate microarray technology for the detection of Burkholderia pseudomallei, Bacillus anthracis and Francisella tularensis antibodies. Carbohydr Res (2008) 0.94
Scaling metabolism from individuals to reef-fish communities at broad spatial scales. Ecol Lett (2014) 0.93
Protein synthesis is required for expression of anthrax lethal toxin cytotoxicity. Infect Immun (1994) 0.93
Clinical recognition and management of patients exposed to biological warfare agents. Clin Lab Med (2001) 0.88
Comparative vaccine efficacy of different isoforms of recombinant protective antigen against Bacillus anthracis spore challenge in rabbits. Vaccine (2006) 0.87
Bacterial filamentation of Yersinia pestis by beta-lactam antibiotics in experimentally infected mice. Arch Pathol Lab Med (1997) 0.86
DNA release as a direct measure of microbial killing. I. Serum bactericidal activity. J Immunol (1975) 0.86
Analysis of the Yersinia pestis V protein for the presence of linear antibody epitopes. Infect Immun (1998) 0.84
Cellular immunity in pyelonephritis: identification of suppressor cell activity of spleen cells in response to concanavalin A and inhibition of lymphocyte-mediated L cell cytotoxicity. J Immunol (1976) 0.84
Experimental prostatitis: relationship to pyelonephritis. J Infect Dis (1972) 0.83
DNA release as a direct measure of microbial killing by phagocytes. Infect Immun (1978) 0.82
Inhibition of mouse peritoneal macrophage DNA synthesis by infection with the arenavirus Pichinde. Infect Immun (1984) 0.81
Processing, assembly and localization of a Bacillus anthracis spore protein. Microbiology (2009) 0.80
Cellular immunity in pyelonephritis: inhibition of the spleen cell response to the mitogen concanavalin A. Cell Immunol (1974) 0.75